Phio Pharmaceuticals Reports Positive PH-762 Phase 1b Safety Results

Phio Pharmaceuticals ( (PHIO) ) has shared an announcement.

On February 10, 2026, Phio Pharmaceuticals reported that an independent Safety Monitoring Committee completed its review of the Phase 1b trial of PH-762 in skin cancers with a positive safety conclusion, finding no serious adverse events or dose-limiting toxicities among 22 patients across five dose-escalation cohorts. The company said the highest dose cohort showed an 85% pathological response rate, with four of six responders achieving complete tumor clearance, supporting continued evaluation of this dose in subsequent studies.

Updated efficacy data from the trial showed a 65% overall response rate in cutaneous squamous cell carcinoma, with 13 of 20 patients classified as pathologic responders and no cases of disease progression reported among any participants. Phio also noted that chemistry, manufacturing and controls work is progressing, with active pharmaceutical ingredient material expected in March 2026 to enable a non-human primate study and plans to begin cGMP manufacturing in the second half of 2026, marking a key step toward potential pivotal trials and reinforcing its development trajectory in immuno-oncology.

The most recent analyst rating on (PHIO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.

Spark’s Take on PHIO Stock

According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.

The score is held down primarily by weak financial performance (no revenue, continued losses and cash burn) and a bearish technical trend (below major moving averages with negative MACD). Offsetting these are constructive corporate developments for PH-762 (positive Phase 1b data and regulatory progress) and a low-debt balance sheet, but valuation remains challenged due to ongoing losses and no dividend support.

To see Spark’s full report on PHIO stock, click here.

More about Phio Pharmaceuticals

Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on immuno-oncology therapeutics using its proprietary INTASYL siRNA gene silencing technology. The company’s lead program, PH-762, targets the PD-1 gene to enhance immune cell–mediated killing of cancer cells and is being evaluated as a potential non-surgical treatment for various skin cancers, including cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.

Phio operates in the oncology drug development space, aiming to position INTASYL-based therapies as novel local treatments that could complement or reduce the need for surgery in skin cancer care. Its ongoing clinical work and manufacturing readiness efforts are key to advancing PH-762 toward later-stage trials and potential pivotal studies.

Average Trading Volume: 375,799

Technical Sentiment Signal: Sell

Current Market Cap: $9.9M

For an in-depth examination of PHIO stock, go to TipRanks’ Overview page.